Pozen

One more under-$10 name that's trending very close to triggering a major breakout trade is Pozen ( POZN), which is a pharmaceutical development company that focuses on migraine treatment through the use of triptans and different delivery mechanisms. This stock has been downtrending over the last six months, with shares off by 24%.

If you take a look at the chart for POZN, you'll see that this stock has dropped sharply from its March high of $6.49 a share to its recent low of $4.55 a share. During that selloff, shares of POZN were consistently making lower highs and lower lows, which is bearish technical price action. That said, shares of POZN have started to rebound off that $4.55 low with the stock hitting a recent high of $5.15 a share. That move is coming with expanded upside volume and now shares of POZN are quickly moving within range of triggering a major breakout trade.

Traders should now look for long-biased trades in POZN if it manages to break out above some near-term overhead resistance at $5.15 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 236,000 shares. If that breakout triggers soon, then POZN will set up to re-test or possibly take out its next major overhead resistance levels at its 50-day moving average of $5.66 to its 200-day moving average at $5.89 a share. Any high volume move above those key moving averages and then above $6.11 will put $6.50 into range for shares of POZN.

Traders can look to buy POZN off weakness to anticipate that breakout and simply use a stop just below some key near-term support levels at $4.65 to $4.55 a share. One can also buy off strength once POZN clears $5.15 with volume and then simply use a stop just below $4.65 a share.

To see more hot under-$10 equities, check out the Stocks Under $10 Setting Up to Explode portfolio on Stockpickr.

-- Written by Roberto Pedone in Winderemere, Fla.

RELATED LINKS:



Follow Stockpickr on Twitter and become a fan on Facebook.

At the time of publication, author had no positions in stocks mentioned.

Roberto Pedone, based out of Madison, Wis., is an independent trader who focuses on technical analysis for small- and large-cap stocks, options, futures, commodities and currencies. Roberto studied international business at the Milwaukee School of Engineering, and he spent a year overseas studying business in Lubeck, Germany. His work has appeared on financial outlets including CNBC.com and Forbes.com. You can follow Pedone on Twitter at www.twitter.com/zerosum24 or @zerosum24.

If you liked this article you might like

Acura Pharmaceuticals (ACUR) Stock Spikes on Development Deal with Bayer Healthcare

3 Stocks Pushing The Drugs Industry Lower

3 Stocks Pushing The Drugs Industry Lower

3 Stocks Advancing The Drugs Industry